Patient Square Capital LP

MENLO PARK, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 10, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$626.7M2026 Q3
Positions23
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.80.6%

Patient Square Capital LP reported 23 positions worth $626.7M as of September 30, 2026 (13F filed November 10, 2026). Largest holding: ROIV (45.0%). Biggest move: reduce ONC ($20.7M).

10 / 23 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ROIVRoivant Sciences$282.0M45.00%7,710,928——+5.6%
▸ 2 RVMDRevolution Medicines$40.2M6.42%196,000——-18.7%
▸ 3 UTHRUnited Therapeutics$34.0M5.42%62,677——+8.5%
▸ 4 ARGXArgenx$26.8M4.28%28,000——-0.8%
▸ 5 PHVSPharvaris N.V.$25.7M4.09%808,644——+2.3%
▸ 6 ABVXAbivax S.A.$24.1M3.84%243,000———
▸ 7 BLTEBelite Bio$22.4M3.57%131,700——-4.3%
▸ 8 MIRMMirum Pharmaceuticals$20.0M3.19%234,000——+7.1%
▸ 9 ZLABZai Lab$15.6M2.49%591,510——-10.9%
▸ 10 DFTXDefinium Therapeutics$14.7M2.34%385,000——-20.8%

Pro Feature

The remaining 13 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Patient Square Capital LP hold as of Q3 2026?

Patient Square Capital LP reported 23 positions worth $626.7M in its Q3 2026 13F filing. Largest positions: ROIV (45.0%), RVMD (6.4%), UTHR (5.4%), ARGX (4.3%) and PHVS (4.1%).

What did Patient Square Capital LP buy in Q3 2026?

New positions: ZLAB, DFTX, CMPS, PCVX and ZNTL (6 in all). Added to: UTHR, ARGX, PHVS, KYMR and BLTE (8 in all).

What did Patient Square Capital LP sell in Q3 2026?

Reduced: ONC, RVMD, ROIV, BNTX and IVA (8 in all). Sold out entirely: XENE, DNTH, EYPT, ARQT and CCCC (6 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.